March 2024 in “Arquivos de Ciências da Saúde da UNIPAR” Onyx® embolization effectively treats facial arteriovenous malformations with minimal complications.
24 citations
,
January 2017 in “International Journal of Trichology”
2 citations
,
March 2012 in “JAMA” Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
January 2018 in “Investigative Ophthalmology & Visual Science”
January 2021 in “Reactions Weekly” Finasteride might cause rare blood clot in brain for baldness patients.
8 citations
,
October 2021 in “The international journal of risk and safety in medicine” The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.
10 citations
,
May 2018 in “Neuropharmacology” Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
8 citations
,
April 2021 in “Journal of Clinical Investigation” Finasteride reduces opioid use and withdrawal symptoms in animals.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
January 2012 in “Yearbook of Dermatology and Dermatologic Surgery” Acne treatment, including isotretinoin, improves quality of life and does not worsen depression.
August 2014 in “DOAJ (DOAJ: Directory of Open Access Journals)” Testosterone and finasteride showed minor cognitive benefits in older men.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
12 citations
,
July 2020 in “International Journal of Pharmaceutics” Iron oxide nanoparticles improve skin penetration and drug release for hair loss treatment.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
2 citations
,
January 2017 in “Düşünen Adam” Agomelatine might help stop hair loss caused by valproate.
June 2013 in “Clinical Neurophysiology” Finasteride improved reflexes and motor activity in rats with liver-related brain issues.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
6 citations
,
May 2012 in “The Journal of Dermatology” Fexofenadine may help treat a difficult type of hair loss.
1 citations
,
January 2021 in “Skin appendage disorders”
February 2025 in “Ciencia Latina Revista Científica Multidisciplinar” Finasteride can help with hair loss and prostate issues but may negatively affect mood and the nervous system.
September 2022 in “Zenodo (CERN European Organization for Nuclear Research)”
3 citations
,
January 2015 in “Journal of drug assessment” Taking five small dutasteride capsules is the same as taking one larger capsule.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
October 2025 in “Reactions Weekly” Finasteride and dutasteride may cause depression and suicidal thoughts.
May 2022 in “Reactions Weekly” February 2024 in “Reactions weekly”
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.